About us

PhD from Stanford University, postdoctoral work at MIT, Harvard, and University of New South Wales. Published in top journals in the field of aging and neurodegeneration. Broad biotech experience in drug discovery, drug development, preclinical studies and clinical trials.

Biopharmaceutical executive and commercial leader with a proven record of success backed by over 20 years of industry experience. Currently Chief Commercial Officer at Roivant Sciences and previously Global Franchise Head and Head of Global Market Access and Pricing for Neurology & Immunology at EMD Serono/Merck KGaA.

Scientist/surgeon at Brigham and Women’s and Boston Children’s Hospitals. Dedicated to translational science and medicine. Unique expertise in the repositioning of approved drugs and the development/characterization of novel/experimental immunotherapeutics. University of Cambridge. Visiting Scientist at Langer and Traverso labs. Koch Institute for Integrative Cancer Research at MIT

Dow Professor Emeritus of Toxicology, Associate Professor Emeritus of Neurology at the University of Michigan. Expert in drug discovery and development for Alzheimer’s and other neurodegenerative diseases.

A former computational biologist at Sana biotechnology, an expert in bioinformatics, UC Berkely doctorate.

Founder of two biotechnology companies. Two IPO's. Harvard Medical School and Johns Hopkins residency. Regenerative medicine expert.

Quantum chemist. Professor of physics at Oregon State University. Expert in electronic and optical properties of organic materials.

Neurosurgeon and psychiatrist. Associate professor of neurosurgery at the University of Texas at Austin.